David J. Straus

12.3k citations

175 papers · 6.5k indexed · h-index 44

Impact in

Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research

Papers in

Pathology and Forensic Medicine 143
- Lymphoma Diagnosis and Treatment 143
Genetics 50
- Chronic Lymphocytic Leukemia Research 48

Co-authors: Craig H. Moskowitz Andrew D. Zelenetz Carol S. Portlock Ariela Noy Joachim Yahalom Paul A. Hamlin Owen A. O’Connor Bayard D. Clarkson
Journals: Blood (49 papers)Journal of Clinical Oncology (32 papers)Cancer (15 papers)British Journal of Haematology (8 papers)The American Journal of Medicine (5 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

David J. Straus

169 papers receiving 6.3k citations

Peers

Countries citing papers authored by David J. Straus

Since Specialization

Citations

This map shows the geographic impact of David J. Straus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Straus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Straus more than expected).

Fields of papers citing papers by David J. Straus

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Straus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Straus. The network helps show where David J. Straus may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David J. Straus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David J. Straus Line = papers co-authored together David J. Straus links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP Blood Advances ·V. Chizchova, Alexandra N. Smith, Matthew J. Maurer, Julie Teruya‐Feldstein, Matthew J. Matasar, Alison J. Moskowitz, David J. Straus, Ariela Noy, M. Lia Palomba, Steven M. Horwitz, Paul A. Hamlin, Carol S. Portlock, James R. Cerhan, Thomas M. Habermann, Gilles Salles, Grzegorz S. Nowakowski, Craig H. Moskowitz, Andrew D. Zelenetz	2024	2
2	CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas PubMed ·Paola Ghione, V. Chizchova, Erel Joffe, M. Lia Palomba, Ariela Noy, Philip Caron, Paul A. Hamlin, Anita Kumar, Matthew J. Matasar, Colette Owens, Alison J. Moskowitz, Lorenzo Falchi, David J. Straus, Steven M. Horwitz, Gilles Salles, Ahmet Doǧan, Andrew D. Zelenetz	2024	1
3	Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma. Journal of Clinical Oncology ·Stephen M. Ansell, David J. Straus, Joseph M. Connors, Wojciech Jurczak, Won-Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan W. Friedberg, Ranjana H. Advani, Martin Hutchings, Andrew M. Evens, Kerry J. Savage, Hyeon‐Seok Eom, Tatyana Feldman, Jeremy S. Abramson, 小陆, Bipin N. Savani, Athanasios Zomas, Keenan Fenton, John Radford	2024	1
4	Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue Blood Advances ·Erel Joffe, Yan Leyfman, Esther Drill, Usman Abdullahi, Andrew D. Zelenetz, M. Lia Palomba, Craig H. Moskowitz, Carol S. Portlock, Ariela Noy, Steven M. Horwitz, John F. Gerecitano, Alison J. Moskowitz, Paul A. Hamlin, Matthew J. Matasar, Anita Kumar, Connie Lee Batlevi, Anas Younes, David J. Straus	2021	7
5	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma Clinical Cancer Research ·Radhakrishnan Ramchandren, Ranjana H. Advani, Stephen M. Ansell, Nancy L. Bartlett, Robert Chen, Joseph M. Connors, Tatyana Feldman, Andres Forero‐Torres, Jonathan W. Friedberg, Ajay K. Gopal, Leo I. Gordon, John Kuruvilla, Kerry J. Savage, Anas Younes, Miriam González Ferrer, Thomas Manley, Keenan Fenton, David J. Straus	2019	30
6	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma Blood ·Sven Borchmann, Erel Joffe, Craig H. Moskowitz, Andrew D. Zelenetz, Ariela Noy, Carol S. Portlock, John F. Gerecitano, Connie Lee Batlevi, Philip Caron, Pamela Drullinsky, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Colette Owens, M. Lia Palomba, Anas Younes, David J. Straus	2019	26
7	Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse Blood Cancer Journal ·Anita Kumar, Fushen Sha, Ahmed Toure, Ahmet Doǧan, Ai Ni, Connie Lee Batlevi, Maria Lia Palomba, Carol S. Portlock, David J. Straus, Ariela Noy, Steven M. Horwitz, Alison J. Moskowitz, Paul A. Hamlin, Craig H. Moskowitz, Matthew J. Matasar, Andrew D. Zelenetz, Anas Younes	2019	76
8	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma Blood ·Deborah M. Stephens, Hongli Li, Heiko Schöder, David J. Straus, Craig H. Moskowitz, Michael LeBlanc, Lisa M. Rimsza, Nancy L. Bartlett, Andrew M. Evens, Ann S. LaCasce, Paul M. Barr, Michael V. Knopp, Eric D. Hsi, John P. Leonard, Brad S. Kahl, Sonali M. Smith, Jonathan W. Friedberg	2019	71
9	Real World Clinical and Economic Burden of Patients with Hodgkin Lymphoma (HL) Who Fail Frontline (FL) Therapy in the US Blood ·David J. Straus, Machaon Bonafede, Joseph Feliciano, Qian Cai, Virginia Noxon, Nicole Princic, Neil C. Josephson, Akshara Richhariya	2017	1
10	Prospective Study of 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma Journal of Nuclear Medicine ·Heiko Schöder, Andrew D. Zelenetz, Paul A. Hamlin, Somali Gavane, Steven M. Horwitz, Matthew J. Matasar, Alison J. Moskowitz, Ariela Noy, Lia Palomba, Carol S. Portlock, David J. Straus, Ravinder K. Grewal, Jocelyn Migliacci, Steven M. Larson, Craig H. Moskowitz	2015	30
11	Interim [¹⁸F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone? Leukemia & lymphoma ·Lale Kostakoğlu, Heiko Schöder, Jeffrey L. Johnson, Nathan C. Hall, Lawrence H. Schwartz, David J. Straus, Ann S. LaCasce, Sin‐Ho Jung, Nancy L. Bartlett, George P. Canellos, Bruce D. Cheson, (unknown)	2012	31
12	Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma Journal of Clinical Oncology ·Craig H. Moskowitz, Heiko Schöder, Julie Teruya‐Feldstein, Camelia S. Sima, Alexia Iasonos, Carol S. Portlock, David J. Straus, Ariela Noy, Maria Lia Palomba, Owen A. O’Connor, Steven M. Horwitz, Sarah A. Weaver, Doreen Richardson, Daniel A. Filippa, James F. Caravelli, Paul A. Hamlin, Andrew D. Zelenetz	2010	225
13	Phase III Placebo-Controlled Trial of Denileukin Diftitox for Patients With Cutaneous T-Cell Lymphoma Journal of Clinical Oncology ·H. Miles Prince, Madeleine Duvic, Ann Martin, Wolfram Sterry, Chalid Assaf, Yijun Sun, David J. Straus, Mark Acosta, A. Negro‐Vilar	2010	152
14	Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas Leukemia & lymphoma ·Myron S. Czuczman, David J. Straus, John G. Gribben, Henning Bredenfeld, Jonathan W. Friedberg, Catherine M. Bollard	2010	6
15	High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imaging British Journal of Haematology ·Craig H. Moskowitz, Joachim Yahalom, Andrew D. Zelenetz, Zhigang Zhang, Daniel A. Filippa, Julie Teruya‐Feldstein, Tarun Kewalramani, Alison J. Moskowitz, Robert D. Rice, Jocelyn Maragulia, Jill Vanak, Tanya Trippett, Paul A. Hamlin, S. Horowitz, Ariela Noy, Owen A. O’Connor, Carol S. Portlock, David J. Straus, Stephen D. Nimer	2010	59
16	Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience Annals of Oncology ·Xinyu Chu, Lindsay M. Jacks, Craig H. Moskowitz, M. B. Kothale, صادق حضرتی, Ariela Noy, C. Portlock, David J. Straus, Andrew D. Zelenetz, Joachim Yahalom	2009	15
17	A Multicenter Experience with Single Agent Bortezomib in Non-Hodgkin’s Lymphoma Reveals Marked Differences in Sub-Type Sensitivity to Proteasome Inhibition. Blood ·Owen A. O’Connor, James R. Wright, Craig H. Moskowitz, Barbara MacGregor‐Cortelli, David J. Straus, Andrew Evans, Jane N. Winter, Omer N. Koç, N. Horvath, Susan Blumel, Julie M. Vose, David P. Schenkein, Andrew D. Zelenetz	2004	16
18	The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide Annals of Oncology ·C. Portlock, Jing Qin, W. S. Lee, Nancy Roistacher, Jane Myers, D Filippa, D C Louie, Andrew D. Zelenetz, James P. O'Brien, Craig H. Moskowitz, Larry Norton, Joachim Yahalom, David J. Straus, Joseph R. Bertino	2004	13
19	On the Use of Cause-Specific Failure and Conditional Failure Probabilities: Examples from Clinical Oncology Data Journal of the American Statistical Association ·Jeffrey J. Gaynor, Eric J. Feuer, 光孝北村, Danny Wu, Claudia Little, David J. Straus, Bayard D. Clarkson, Murray F. Brennan	1993	396
20	Central nervous system metastases from non-hodgkin's lymphoma: Treatment and prophylaxis The American Journal of Medicine ·Lawrence D. Recht, David J. Straus, Constance Cirrincione, Howard T. Thaler, Jerome B. Posner	1988	81

About David J. Straus

David J. Straus is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Neurology and Dermatology, having authored 175 papers that have together received 6.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (143 papers), Chronic Lymphocytic Leukemia Research (48 papers), Viral-associated cancers and disorders (41 papers), Lung Cancer Treatments and Mutations (36 papers), CNS Lymphoma Diagnosis and Treatment (31 papers), Cutaneous lymphoproliferative disorders research (14 papers), T-cell and Retrovirus Studies (12 papers) and Acute Lymphoblastic Leukemia research (9 papers). The work is most often cited by research in Pathology and Forensic Medicine (4.6k citations), Genetics (1.6k citations), Neurology (1.6k citations), Oncology (2.9k citations) and Dermatology (469 citations). David J. Straus has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Craig H. Moskowitz, Andrew D. Zelenetz, Carol S. Portlock, Ariela Noy, Joachim Yahalom, Paul A. Hamlin, Owen A. O’Connor, Bayard D. Clarkson, Daniel A. Filippa and Jing Qin. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer, British Journal of Haematology and The American Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact